New Cancer-Fighting Molecule Turns Tumors’ Own Energy Against Them

This Molecule Doesn’t Starve Tumors. It Overfeeds Them.

Cancer cells are notorious energy hogs. To grow fast, they hijack the body’s sugar-burning machinery and run it at full speed, a behavior scientists call the Warburg effect. For decades, researchers tried to exploit that greediness as a weakness, but tumors kept adapting. Now, scientists have taken a different approach with a molecule that turns cancer’s own fuel supply against it.

A study accepted by Nature Chemical Biology describes a compound called XJ-4-85, built from two parts: one locks onto a key sugar-burning protein in cancer cells and cranks it into overdrive, while the other releases a payload called XJ-4-119 that disrupts the mitochondrial breakdown of long-chain fatty acids. The work is still preclinical, and XJ-4-85 has not been tested as a cancer treatment in humans.

For scientists, the concept is counterintuitive. Turning a cancer-fueling process up rather than shutting it down runs against the usual playbook. Flooding cancer cells with a sugar-metabolism byproduct, while interfering with one route for using long-chain fats as fuel, appears to disrupt two parts of cancer-cell metabolism at once, making cells less able to sustain growth.

Cancer’s Sugar Addiction Has Resisted Treatment For Decades

Most cells can burn either sugar or fat, switching between the two depending on availability. Cancer cells develop a powerful preference for sugar. A protein called PFK1 acts as the throttle on that engine, and in many cancers it runs hot.

Blocking PFK1 sounds logical, but cancer cells are crafty. Shut down one fuel source, and they often pivot to burning other nutrients instead. The team behind XJ-4-85 took a different angle: rather than blocking PFK1, they activated it, specifically targeting a version called PFKL, the form most common in the liver but also active in certain cancers.

A Single Molecule Locks Onto One Target With Unusual Precision

XJ-4-85 was designed using a chemistry approach that lets molecules bond permanently to specific proteins in living cells. That bond was unusually selective: among roughly 9,000 measured protein sites, a single spot on PFKL was the only one with significant engagement, and that selectivity held across multiple human and mouse cell types.

When XJ-4-85 binds to PFKL, it locks the protein into its active shape, keeping the sugar-burning engine running at high speed. That produces a buildup of a sugar breakdown byproduct called fructose-1,6-bisphosphate. Using a specially designed sensor, researchers watched levels of that byproduct spike in real time inside living cancer cells.

Once XJ-4-85 snaps onto PFKL, it releases a fragment called XJ-4-119, which travels to CPT2, a gatekeeper protein on the inner mitochondrial membrane that controls the breakdown of long-chain fatty acids. To find that target, researchers heated treated cells and tracked which proteins resisted falling apart, since a protein bound to a drug holds together under heat better than one sitting alone. Out of more than 7,000 proteins tested this way, CPT2 stood out clearly above every other one. Treated cells accumulated fat-burning byproducts consistent with CPT2 being blocked, and cells already burning sugar hardest before treatment appeared especially vulnerable to this combined disruption.

The Compound Slowed Tumor Growth in Mice With Melanoma

To see whether this worked in a living animal, researchers implanted melanoma cells into mice. Melanoma cells were chosen partly because they showed high baseline levels of that sugar byproduct, which could make them more vulnerable to XJ-4-85.

Once tumors reached a measurable size, mice received daily injections of XJ-4-85, XJ-4-119 alone, a control compound, or a vehicle. After two weeks, mice on XJ-4-85 had significantly smaller tumors than every other group. XJ-4-119 alone was less effective at equivalent doses, supporting the idea that activating PFKL does meaningful work beyond just delivering the CPT2-blocking piece.

To confirm both targets mattered, researchers genetically removed PFKL or CPT2 from the melanoma cells before implanting them. Removing PFKL sharply cut effectiveness: after nine days, tumors in mice missing PFKL were roughly five times the size of tumors in mice that still had it, showing the drug’s punch had mostly vanished. Removing CPT2 also reduced the effect, though less completely. Together, the experiments showed PFKL was essential for most of the effect and CPT2 also contributed.

Key Questions Remain Before Any Human Testing Could Begin

Mice tolerated treatment well over the two-week study, with no obvious signs of distress or weight loss. That is reassuring, though it falls short of proving safety over longer treatment or in people.

This approach borrows a page from antibody-drug conjugates, a cancer drug class that pairs a targeting piece with a toxic payload. XJ-4-85 swaps that piece for a small molecule that slips inside cells and reaches targets an antibody never could, a strategy the researchers call an electrophile-drug conjugate.

Plenty remains unsettled. Exactly why activating PFKL slows tumors so effectively in animals is not fully worked out, and cancer cells facing this metabolic squeeze may find workarounds over time, as they have with other treatments. Nobody has tested both PFKL and CPT2 knocked out at once, and a more potent, drug-ready version would likely be needed before this could reach a clinical trial.

Still, the result is a genuinely creative twist on a stubborn problem: instead of starving a tumor’s engine, this molecule floors the gas pedal and cuts the brakes at once. Whether that idea becomes a real treatment will come down to years of further testing.

---

Disclaimer: This article summarizes findings from a peer-reviewed preclinical study. The compound described has not been tested in humans, is not an approved treatment, and should not be interpreted as medical advice. Readers with questions about cancer treatment should consult a qualified healthcare provider.

---